Immunomodulating Agents clinical trials
A class of medicines: the studies that test any of its 2 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Get an email when these change. Save the immunomodulating agents studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
Studies by the year they started
61 studies that test it; most in 2026 (12)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 7 |
| 2018 | 1 |
| 2019 | 8 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 3 |
| 2025 | 4 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 43 · Other 18
TG Therapeutics, Inc. (22) · Pfizer (11) · Arena Pharmaceuticals (8) · City of Hope Medical Center (2) · Johns Hopkins University (2) · The First Affiliated Hospital of Soochow University (1) · Jennifer R. Brown, MD, PhD (1) · Everstar Therapeutics Limited (1)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 61
- Ublituximab in Autoantibody Positive Immune Mediated Necrotizing MyopathyRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07103746Written as Ublituximab
- Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaRecruitingPhase 2TG Therapeutics, Inc.NCT07680946Written as Ublituximab
- A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)RecruitingPhase 2TG Therapeutics, Inc.NCT07503873Written as Ublituximab
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)RecruitingPhase 2TG Therapeutics, Inc.NCT07673744Written as Ublituximab
- Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisRecruitingPhase 2/3TG Therapeutics, Inc.NCT07220252Written as Ublituximab
- A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisRecruitingPhase 2PfizerNCT05287126Written as Etrasimod
- A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative ColitisRecruitingPhase 2PfizerNCT07470879Written as Etrasimod
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabRecruitingPhase 3TG Therapeutics, Inc.NCT05877963Written as Ublituximab
- An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression DisorderNot yet recruitingPhase 2Jonathan SantoroNCT07812181Written as Ublituximab
- Etrasimod as Prevention of PouchitisRecruitingPhase 2Maia KayalNCT07486921Written as etrasimod
- Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UCNot yet recruitingPhase 4Sir Run Run Shaw HospitalNCT07782242Written as Etrasimod
- Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple SclerosisRecruitingNot applicableUniversity of Maryland, BaltimoreNCT06864936Written as Ublituximab
- Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisRecruitingPhase 4Johns Hopkins UniversityNCT07389590Written as Ublituximab
- Ublituximab (Briumvi) for Early Forms of Relapsing Multiple SclerosisRecruitingPhase 4Northwestern UniversityNCT07225361Written as Ublituximab
- Effects of Ublituximab on Motor Functions in Multiple SclerosisRecruitingEarly Phase 1Georgia State UniversityNCT06629428Written as Ublituximab
- An Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 3PfizerNCT03950232Written as Etrasimod
- An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisActive, not recruitingPhase 3TG Therapeutics, Inc.NCT04130997Written as Ublituximab
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3TG Therapeutics, Inc.NCT07211633Written as Ublituximab
- A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding WomenCompletedPhase 1PfizerNCT07153159Written as Etrasimod
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingPhase 2City of Hope Medical CenterNCT04783415Written as Ublituximab
See all 61 studies that test one of the immunomodulating agents →
Codes
What other systems call Immunomodulating Agents · ClinicalTrials.gg INT006862
- MeSH (NLM) D000091369Immunomodulating AgentsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000091369 | Immunomodulating Agents | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.